← Leaderboards
David Tuveson
University Of Pennsylvania
$22,023,736
Attributed
$26,066,880
Total exposure
18
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$70,716,602 · 19
By mechanism
P30$52,609,720 · 10
R01$11,234,516 · 5
U01$4,226,189 · 1
U10$2,012,121 · 1
UG3$398,398 · 1
P20$235,658 · 1
Top collaborators
- Laurence H Baker5 shared
- Edison Tak-Bun Liu5 shared
- Paul Robson5 shared
- John Edward Moses2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Glenn Walter$7,015,730
- Mary Beth Leonard$17,530,683
- Prateek Sharma$50,477
- Stephen William Tuttle$381,150
- Katharine June Bar$15,418,177
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsLaboratoriesProgramsResource SharingDiagnosisCancer CenterCancer Center Support GrantCollaborationsTumorInnovationResearch PersonnelMemberTechnologyFundingMolecularPancreatic Ductal AdenocarcinomaCellsMalignant Neoplasm Of PancreasOrganoidsLeadershipMouse ModelRecruitAnticancer ResearchNovel Therapeutics
Grant awards (64)
CSHL Cancer Center Support Grant$4,495,455
P30 · FY2025 · CA · contact PI
Developmental Funds$821,591
P30 · FY2025 · CA · contact PI
Fibroblast Heterogeneity in Pancreatic Cancer$796,363
R01 · FY2025 · CA · contact PI
SOAT1 as a targetable dependency in Pancreatic Adenocarcinoma$778,873
R01 · FY2025 · CA · contact PI
Discovery of Natural Products and Natural Product Derivatives as Inhibitors of KLK6 to Prevent the Progression of Preneoplastic Ductal Pancreatic Cancer$398,398
UG3 · FY2025 · CA
Leadership, Planning and Evaluation$270,104
P30 · FY2025 · CA · contact PI
Administration$204,397
P30 · FY2025 · CA · contact PI
Environmental triggers of early-onset colorectal cancer: interactions between microplastics and pks+ E coli in early-life gut colonization$192,000
P30 · FY2025 · CA · contact PI
CSHL Cancer Center Support Grant$4,495,455
P30 · FY2024 · CA · contact PI
Developmental Funds$793,001
P30 · FY2024 · CA · contact PI
Fibroblast Heterogeneity in Pancreatic Cancer$756,549
R01 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$269,087
P30 · FY2024 · CA · contact PI
Administration$206,666
P30 · FY2024 · CA · contact PI
CSHL Cancer Center Support Grant$4,495,455
P30 · FY2023 · CA · contact PI
Developmental Funds$821,591
P30 · FY2023 · CA · contact PI
Fibroblast Heterogeneity in Pancreatic Cancer$780,205
R01 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$270,104
P30 · FY2023 · CA · contact PI
Administration$204,397
P30 · FY2023 · CA · contact PI
CSHL Cancer Center Support Grant$4,495,455
P30 · FY2022 · CA · contact PI
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity$823,816
U01 · FY2022 · CA · contact PI
Developmental Funds$821,591
P30 · FY2022 · CA · contact PI
Fibroblast Heterogeneity in Pancreatic Cancer$779,963
R01 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$270,104
P30 · FY2022 · CA · contact PI
Administration$204,397
P30 · FY2022 · CA · contact PI
CSHL Cancer Center Support Grant$4,495,455
P30 · FY2021 · CA · contact PI
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity$844,970
U01 · FY2021 · CA · contact PI
Developmental Funds$821,591
P30 · FY2021 · CA · contact PI
Fibroblast Heterogeneity in Pancreatic Cancer$818,876
R01 · FY2021 · CA · contact PI
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response$615,683
R01 · FY2021 · CA · contact PI
Leadership, Planning and Evaluation$270,104
P30 · FY2021 · CA · contact PI
Administration$204,397
P30 · FY2021 · CA · contact PI
CSHL Cancer Center Support Grant$4,403,952
P30 · FY2020 · CA · contact PI
Development$863,047
P30 · FY2020 · CA · contact PI
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity$848,343
U01 · FY2020 · CA · contact PI
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response$615,683
R01 · FY2020 · CA · contact PI
Administration and Senior Leadership$607,324
P30 · FY2020 · CA · contact PI
Planning and Evaluation$36,505
P30 · FY2020 · CA · contact PI
CSHL Cancer Center Support Grant$4,403,952
P30 · FY2019 · CA · contact PI
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity$828,044
U01 · FY2019 · CA · contact PI
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response$597,211
R01 · FY2019 · CA · contact PI
CSHL Cancer Center Support Grant$4,371,458
P30 · FY2018 · CA · contact PI
CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity$881,016
U01 · FY2018 · CA · contact PI
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response$615,683
R01 · FY2018 · CA · contact PI
Integrated Translational Cancer Science Center$404,730
U10 · FY2018 · CA · contact PI
Pilot 2: Organoids to investigate Pancreatic Cancer in under represented minorities$58,468
P20 · FY2018 · CA · contact PI
CSHL Cancer Center Support Grant$4,395,404
P30 · FY2017 · CA · contact PI
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer$552,684
R01 · FY2017 · CA · contact PI
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response$510,684
R01 · FY2017 · CA · contact PI
Integrated Translational Cancer Science Center$404,730
U10 · FY2017 · CA · contact PI
Pilot 2: Organoids to investigate Pancreatic Cancer in under represented minorities$58,786
P20 · FY2017 · CA · contact PI
CSHL Cancer Center Support Grant$4,405,681
P30 · FY2016 · CA · contact PI
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer$560,492
R01 · FY2016 · CA · contact PI
Integrated Translational Cancer Science Center$397,716
U10 · FY2016 · CA · contact PI
Pilot 2: Organoids to investigate Pancreatic Cancer in under represented minorities$59,098
P20 · FY2016 · CA · contact PI
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer$555,711
R01 · FY2015 · CA · contact PI
Integrated Translational Cancer Science Center$404,945
U10 · FY2015 · CA · contact PI
Pilot 2: Organoids to investigate Pancreatic Cancer in under represented minorities$59,306
P20 · FY2015 · CA · contact PI
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer$555,711
R01 · FY2014 · CA · contact PI
Integrated Translational Cancer Science Center$400,000
U10 · FY2014 · CA · contact PI
Mutant mouse models of exocrine pancreatic cancer$209,928
R01 · FY2008 · CA · contact PI
Mutant mouse models of exocrine pancreatic cancer$209,928
R01 · FY2007 · CA · contact PI
Mutant mouse models of exocrine pancreatic cancer$298,713
R01 · FY2006 · CA · contact PI
Mutant mouse models of exocrine pancreatic cancer$306,455
R01 · FY2005 · CA
Mutant mouse models of exocrine pancreatic cancer$319,121
R01 · FY2004 · CA